Understanding PSMA PET-CT for Prostate Cancer
An advanced imaging scan that helps determine where prostate cancer is located and supports treatment planning.
PSMA PET-CT is an advanced imaging scan that helps determine whether prostate cancer is confined to the prostate or has spread to lymph nodes, bones, or other parts of the body. While not required for every patient, it plays an important role in selected situations where the results may influence diagnosis, staging, and treatment planning.
What is a PSMA PET-CT?
PSMA PET-CT combines two imaging technologies into a single examination:
- PET (Positron Emission Tomography) detects a radioactive tracer that binds to Prostate-Specific Membrane Antigen (PSMA), a protein commonly found in higher amounts on prostate cancer cells.
- CT (Computed Tomography) provides detailed anatomical images that show exactly where areas of tracer uptake are located.
Together, these images allow doctors to identify areas that may represent prostate cancer with greater precision than conventional imaging in many clinical situations.
Although the names sound similar, PSA (Prostate-Specific Antigen) and PSMA (Prostate-Specific Membrane Antigen) are different. PSA is measured with a blood test, whereas PSMA is a protein on prostate cells that can be targeted by specialised imaging tracers.
Why is PSMA PET-CT performed?
Not every man diagnosed with prostate cancer requires a PSMA PET-CT.
Instead, the scan is usually considered when the additional information is likely to influence clinical decision-making.
Your doctor may recommend PSMA PET-CT to:
- Assess whether prostate cancer has spread beyond the prostate.
- Evaluate lymph node involvement.
- Look for cancer that has spread to the bones or other organs.
- Investigate a rising PSA after previous treatment.
- Accurately determine the stage of prostate cancer before treatment.
- Provide additional information before planning treatment in selected patients.
Whether a PSMA PET-CT is appropriate depends on several factors, including your PSA level, MRI findings, biopsy results, Grade Group, and overall risk category.
When is PSMA PET-CT usually recommended?
The scan may be discussed in situations such as:
Newly diagnosed prostate cancer
For some men with intermediate- or high-risk prostate cancer, PSMA PET-CT may provide additional information about whether the disease remains confined to the prostate or has spread elsewhere.
Rising PSA after treatment
After surgery or radiotherapy, a rising PSA may suggest recurrent prostate cancer. PSMA PET-CT can sometimes identify where recurrence has occurred, even when the PSA level is relatively low.
Further assessment in selected situations
Occasionally, PSMA PET-CT may help clarify findings from MRI, CT, or other investigations when further information is needed.
Not everyone with prostate cancer will benefit from this scan. For men with low-risk localised disease, it often does not change management.
How is PSMA PET-CT different from MRI?
MRI and PSMA PET-CT answer different clinical questions and are often complementary.
| MRI Prostate | PSMA PET-CT |
|---|---|
| Examines the prostate gland in detail | Looks for prostate cancer in lymph nodes, bones and other parts of the body |
| Helps detect suspicious lesions before biopsy | Helps determine whether cancer has spread |
| Assesses local anatomy and tumour extent | Assesses regional and distant disease |
| Commonly used early during diagnosis | Usually performed after prostate cancer has been diagnosed or when recurrence is suspected |
One test does not replace the other. Instead, they provide different pieces of information that help doctors understand the disease more completely.
Can PSMA PET-CT replace a prostate biopsy?
No.
A prostate biopsy remains the only way to confirm the diagnosis of prostate cancer by examining tissue under a microscope.
Although PSMA PET-CT is highly sensitive for detecting many prostate cancers, imaging alone cannot establish the diagnosis. In most situations, biopsy and imaging are complementary investigations rather than alternatives.
Is PSMA PET-CT always accurate?
PSMA PET-CT is among the most sensitive imaging techniques currently available for prostate cancer, but no investigation is perfect.
Some prostate cancers may show little or no PSMA uptake. Conversely, certain benign conditions or non-prostate cancers may occasionally demonstrate increased uptake.
For this reason, PSMA PET-CT findings are always interpreted alongside your:
- Medical history
- PSA level
- MRI findings
- Biopsy results
- Physical examination
- Other imaging studies
The scan is one part of the overall clinical assessment rather than a standalone test
What happens during a PSMA PET-CT scan?
A small amount of radioactive tracer is injected into a vein in your arm.
After allowing time for the tracer to circulate, you will undergo the scan while lying comfortably on the imaging table.
The scanning itself is painless and usually takes around 20 to 40 minutes, although the entire appointment—including preparation and waiting time—typically lasts two to three hours.
You will receive specific instructions before your appointment regarding eating, drinking, medications, and hydration.
What do the results tell your doctor?
The purpose of PSMA PET-CT is to provide a clearer picture of where prostate cancer is located.
The scan may help determine whether the cancer appears:
- Confined to the prostate.
- Involving nearby lymph nodes.
- Spread to the bones.
- Spread to other organs.
- Recurrent after previous treatment.
This information contributes to staging and helps doctors discuss appropriate management options.
The scan itself does not treat prostate cancer. Instead, it provides information that supports clinical decision-making.
Limitations of PSMA PET-CT
While PSMA PET-CT has significantly improved prostate cancer imaging, it also has limitations.
It may not detect every prostate cancer, particularly very small deposits or uncommon tumour subtypes with low PSMA expression. Similarly, not every area of increased tracer uptake represents prostate cancer.
Like all investigations, PSMA PET-CT should be interpreted in the context of the overall clinical picture rather than in isolation.
Frequently Asked Questions
Is PSMA PET-CT painful?
No. Apart from the small needle used for the injection, the scan itself is painless.
Does everyone with prostate cancer need a PSMA PET-CT?
No. Many men with low-risk localised prostate cancer do not require this investigation. It is generally recommended only when the results are expected to influence management.
Is PSMA PET-CT better than a bone scan?
In many situations, PSMA PET-CT has been shown to detect prostate cancer spread more accurately than conventional CT and bone scans. However, the most appropriate imaging investigation depends on the individual clinical situation and current treatment recommendations.
Can PSMA PET-CT detect recurrent prostate cancer?
Yes. It is commonly used to investigate a rising PSA after surgery or radiotherapy and may identify where recurrent disease is located.
Is the radioactive tracer safe?
The scan uses a small amount of radioactive tracer. For patients in whom the investigation is clinically indicated, the expected diagnostic benefits generally outweigh the small risks associated with radiation exposure.
Is PSMA PET-CT available in Malaysia?
Yes. PSMA PET-CT is available at selected centres in Malaysia. Your treating specialist can advise whether the scan is appropriate for your situation and where it can be performed.
How long does it take to receive the results?
The scan images are interpreted by a nuclear medicine physician or radiologist with expertise in PET imaging. The report is usually available within a few days, although timing may vary between centres.
Understanding Your PSMA PET-CT Results
A PSMA PET-CT provides valuable information about the location and extent of prostate cancer, but the findings are only one part of the overall assessment. Your scan results should be interpreted alongside your PSA level, MRI, biopsy findings, medical history, and individual circumstances to guide informed decision-making.
If you have recently undergone a PSMA PET-CT or have been advised to have one, discussing the findings with your treating urologist can help you understand what the results mean and how they may influence your treatment options.